Avacta Group PLC - Wetherby-based biotherapeutics firm - Expands partnership with Daewoong Pharmaceutical Co Ltd and joint venture AffyXell Therapeutics for development of stem cell treatments including Avacta's Affimer therapy for treating seriously ill patients with Covid-19.
Current stock price: 145.50 pence
Year-to-date change: eightfold rise from 17.25p
By Dayo Laniyan; email@example.com
Copyright 2020 Alliance News Limited. All Rights Reserved.